Important Recognition for Dutch Prognostic Breast Cancer Test MammaPrint(R)
AMSTERDAM, the Netherlands, December 4 /PRNewswire/ -- TIME Magazine has named a new Dutch breast cancer test as one of the best inventions of 2007. This so called "Cancer's Crystal Ball" (MammaPrint(R)) invented and developed by the International company Agendia, gives additional information on the patient's own tumor to support the choice of treatment for that specific patient providing hope to all women who have been diagnosed with breast cancer.
"We are very pleased that we can help millions of women and that TIME has recognized our contribution to the advancement of health care across the globe, most notably in the field of oncology," said Bernhard Sixt, CEO and founder of Agendia. "This honour is a testament to our ongoing commitment to developing state-of-the-art technology for the benefit of cancer patients - not just in the field of breast cancer. In time, I think we'll be able to reach more people than ever before."
The Breast Cancer Test (MammaPrint(R)) measures the activity levels of 70 genes in a sample taken from a woman's surgically-removed breast cancer tumour. It then uses a specific algorithm to determine whether there is a low-risk or high-risk of the cancer spreading to another part of the body. The result can be used to assist physicians in identifying the most suitable treatment and often means that less aggressive therapies can be applied. The Breast Cancer Test is the first test of its kind to have received market clearance by the FDA.
About Agendia
Agendia, located in Amsterdam, the Netherlands, is a world leader in
gene expression analysis-based diagnostics with three products on the
market. The company focuses on the development and commercialization of
diagnostic tests using tumour gene expression profiling. Agendia was the
first company to commercialize such prognostic test - MammaPrint(R) - that
predicts the risk of breast c
'/>"/>
| SOURCE Agendia BV Copyright©2007 PR Newswire. All rights reserved |